OPCH: Growth momentum, portfolio diversification, and new therapies drive future opportunities
Momentum has stabilized with growth in both acute and specialty therapies, supported by a diversified portfolio and strong hospital relationships. Biosimilar competition and new rare/orphan therapies are expected to drive future growth, while regulatory changes and capital allocation remain focused…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.